NTRK gene fusion testing and management in lung cancer Review
| Authors: | Repetto, M.; Chiara Garassino, M.; Loong, H. H.; Lopez-Rios, F.; Mok, T.; Peters, S.; Planchard, D.; Popat, S.; Rudzinski, E. R.; Drilon, A.; Zhou, C. |
| Review Title: | NTRK gene fusion testing and management in lung cancer |
| Abstract: | Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed to treat tumours with NTRK gene fusions. Larotrectinib and entrectinib are first-generation TRK inhibitors that have demonstrated efficacy in patients with TRK fusion lung cancers. Genomic testing is recommended for all patients with metastatic non-small cell lung cancer for optimal drug therapy selection. Multiple testing methods can be employed to identify NTRK gene fusions in the clinic and each has its own advantages and limitations. Among these assays, RNA-based next-generation sequencing (NGS) can be considered a gold standard for detecting NTRK gene fusions; however, several alternatives with minimally acceptable sensitivity and specificity are also available in areas where widespread access to NGS is unfeasible. This review highlights the importance of testing for NTRK gene fusions in lung cancer, ideally using the gold-standard method of RNA-based NGS, the various assays that are available, and treatment algorithms for patients. © 2024 The Authors |
| Keywords: | protein expression; genetics; review; diarrhea; gold standard; sensitivity and specificity; sensory neuropathy; protein kinase inhibitor; nausea; vomiting; carcinoma, non-small-cell lung; lung neoplasms; myalgia; peripheral neuropathy; lung cancer; central nervous system; carcinogenesis; dizziness; protein kinase inhibitors; lung tumor; patient care; gene identification; gene fusion; oncogene proteins, fusion; muscle weakness; genomics; drug therapy; genetic screening; ataxia; dysgeusia; brain derived neurotrophic factor receptor; receptor, trkb; non small cell lung cancer; fusion protein; molecularly targeted therapy; procedures; protein tyrosine kinase a; tropomyosin; high throughput sequencing; body weight disorder; receptor, trka; high-throughput nucleotide sequencing; humans; human; rna sequencing; entrectinib; larotrectinib; ntrk gene fusion; ntrk gene; trk fusion; oncogene fusion protein; taletrectinib; ntrk1 protein, human |
| Journal Title: | Cancer Treatment Reviews |
| Volume: | 127 |
| ISSN: | 0305-7372 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-06-01 |
| Start Page: | 102733 |
| Language: | English |
| DOI: | 10.1016/j.ctrv.2024.102733 |
| PUBMED: | 38733648 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- MSK corresponding author is Matteo Repetto -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work